Cell-based therapeutic strategies for multiple sclerosis

Marcelo Pasquini, Stephen C. Reingold, Jeffrey A. Cohen, International Conference on Cell-Based Therapies for Multiple Sclerosis

Research output: Contribution to journalReview article (Academic Journal)peer-review

127 Citations (Scopus)
399 Downloads (Pure)


The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of endogenous stem cells to enhance their reparative capabilities, and transplantation of oligodendrocyte progenitor cells, have generated substantial interest as novel therapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervous system in multiple sclerosis. Each approach has potential advantages but also safety concerns and unresolved questions. Moreover, clinical trials of cell-based therapies present several unique methodological and ethical issues. We summarize here the status of cell-based therapies to treat multiple sclerosis and make consensus recommendations for future research and clinical trials.

Original languageEnglish
Pages (from-to)2776-2796
Number of pages21
Issue number11
Early online date21 Jul 2017
Publication statusPublished - 1 Nov 2017


  • clinical trials
  • medical ethics
  • multiple sclerosis and neuroinflammation
  • remyelination
  • stem cells


Dive into the research topics of 'Cell-based therapeutic strategies for multiple sclerosis'. Together they form a unique fingerprint.

Cite this